Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tafuto

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Haematologica|July 1, 1992
CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomasG Abate, S Tafuto, A Romano, et al.
Journal of Biological Regulators and Homeostatic Agents|January 1, 1994
Interleukin-6: biological features and clinical implicationsS Tafuto, I Silvestri, P D'Andrea, et al.
European Journal of Haematology|January 1, 1995
Three-year results of MIM salvage treatment for refractory/relapsed intermediate grade NHLG Abate, S Tafuto, G Marcacci, et al.
Cancer Research|July 1, 1989
Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancerG Parrilli, R V Iaffaioli, M Martorano, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapyS Tafuto, G Abate, P D'Andrea, et al.
Blood|October 1, 1993
Interleukin-3 in vivo: kinetic of response of target cellsM Aglietta, F Sanavio, A Stacchini, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2005
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II studyP Comella, B Massidda, S Palmeri, et al.
Journal of Translational Medicine|May 5, 2016
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinomaC De Divitiis, C von Arx, A M Grimaldi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology GroupP Comella, E Crucitta, F De Vita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2005
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trialP Comella, B Massidda, G Filippelli, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Haematologica|July 1, 1992
CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomasG Abate, S Tafuto, A Romano, et al.
Journal of Biological Regulators and Homeostatic Agents|January 1, 1994
Interleukin-6: biological features and clinical implicationsS Tafuto, I Silvestri, P D'Andrea, et al.
European Journal of Haematology|January 1, 1995
Three-year results of MIM salvage treatment for refractory/relapsed intermediate grade NHLG Abate, S Tafuto, G Marcacci, et al.
Cancer Research|July 1, 1989
Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancerG Parrilli, R V Iaffaioli, M Martorano, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapyS Tafuto, G Abate, P D'Andrea, et al.
Blood|October 1, 1993
Interleukin-3 in vivo: kinetic of response of target cellsM Aglietta, F Sanavio, A Stacchini, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2005
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II studyP Comella, B Massidda, S Palmeri, et al.
Journal of Translational Medicine|May 5, 2016
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinomaC De Divitiis, C von Arx, A M Grimaldi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology GroupP Comella, E Crucitta, F De Vita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2005
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trialP Comella, B Massidda, G Filippelli, et al.
Pageof 2